Insulin and oral agents for managing cystic fibrosis-related diabetes

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 4, 2016, Pages

  Onady, Gary M ^a   Stolfi, Adrienne ^b  

^a WRIGHT STATE UNIVERSITY   (United States)

^b CHILDREN S MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT; PLACEBO; REPAGLINIDE; ANTIDIABETIC AGENT; CARBAMIC ACID DERIVATIVE; PIPERIDINE DERIVATIVE;

BODY MASS; CYSTIC FIBROSIS; DATA BASE; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; LUNG FUNCTION; MORTALITY; NUTRITIONAL STATUS; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SECONDARY INFECTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WEIGHT CONTROL; COMPLICATION; HYPERGLYCEMIA; META ANALYSIS; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADMINISTRATION, ORAL; CARBAMATES; CYSTIC FIBROSIS; DIABETES MELLITUS; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN GLARGINE; INSULIN, ISOPHANE; PIPERIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84963704568     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004730.pub4     Document Type: Review

References (51)

1. Ballmann M, Hubert D, Assael BM, Kronfeld K, Honer M, Holl RW, et al. Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus. BMC Pediatrics 2014;14:70. [CENTRAL: 1000301; CFGD Register: CO53c; CRS: 5500131000000019; JID:: 100967804; OID: [Other ID]: NLM: PMC3975280; PMCID:: PMC3975280; PUBMED: 24620855; SI:: ClinicalTrials.gov/NCT00662714]
2. Ballmann M, Hubert D, Assael BM, Mosnier-Pudar H, Barao Ocampo M, Scheunig N, et al. Repaglinide versus insulin in the treatment of CFRD diagnosed by screening: an open prospective randomized study [abstract]. Pediatric Pulmonology 2013;48 Suppl 26:421, Abstract no: 582. [CENTRAL: 962122; CFGD Register: CO53b; CRS: 5500125000000394]
3. Ballmann M, Hubert D, Assael BM, Mosnier-Pudar H, Smaczny C, Kessler L, et al. Treatment of early diagnosed CFRD with oral drugs verus insulin: An open prospective randomized study [abstract]. Journal of Cystic Fibrosis 2013;12 Suppl 1:S32, Abstract no: WS16.1. [CENTRAL: 962115; CFGD Register: CO53a; CRS: 5500100000011659]
4. Schmid K, Fink K, Holl RW, Hebestreit H, Ballmann M. Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society 2014;13(1):80-5. [CENTRAL: 1000302; CFGD Register: CO53d; CRS: 5500131000000020; JID: 101128966; PUBMED: 23809507; SI: ClinicalTrials.gov/NCT00662714]
5. Grover P, Thomas W, Moran A. Glargine versus NPH insulin in cystic fibrosis related diabetes. Journal of Cystic Fibrosis 2008;7(2):134-6. [CFGD Register: CO39]
6. Milla CE, Phillips J, Moran A. Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD [abstract]. Pediatric Pulmonology 2001;32 (Suppl 22):335. [CFGD Register: CO34a]
7. Moran A, Phillips J, Milla C. Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care 2001;24(10):1706-10. [CFGD Register: CO34b]
8. Moran A, Pekow P, Grover P, Zorn M, Slovis B, Pilewski J, et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care 2009;32(10):1783-8. [CFGD Register: CO43]
9. Beaudoin N, Bouvet GF, Rabasa-Lhoret R, Berthiaume Y. Effects of a partially supervised combined exercise program on glycemic control in cystic fibrosis: pilot study [abstract]. Pediatric Pulmonology 2015;50 Suppl 41:367, Abstract no: 466.
10. Borowitz D, Goss C, Limauro S, Murray F, Casey S, Cohen M. A dose-ranging study of efficacy of TheraCLEC-Total for treatment of pancreatic insufficiency [abstract]. Pediatric Pulmonology 2005;40 (Suppl 28):348. [CFGD Register: GN203a]
11. Borowitz D, Goss CH, Limauro S, Murray F, Casey S, Cohen M, et al. A phase 2 study of TheraCLEC-Total enzymes in CF patients with pancreatic insufficiency (PI) [abstract]. Pediatric Pulmonology 2005;40 (Suppl 28):142. [CFGD Register: GN203b]
12. Borowitz D, Konstan MW, Goss C, Limauro SE, Murray FT. Enhanced coefficient of fat absorption using a novel pancreatic enzyme preparation, ALTU-135, with concomitant use of a proton pump inhibitor [abstract]. Journal of Cystic Fibrosis 2006;5 Suppl:S56. [CFGD Register: CO203d]
13. Borowitz D, Konstan MW, Goss C, Limauro SE, Murray FT, Casey S, et al. Treatment with ALTU-135 results in a positive inverse relationship between coefficient of fat absorption with stool weight in subjects with cystic fibrosis-related pancreatic insufficiency [abstract]. Journal of Cystic Fibrosis 2006;5 Suppl:S56. [CFGD Register: GN203c]
14. Murray FT, Borowitz D, Konstan MW, Limauro SE, Goss C. Changes in coefficients of fat and nitrogen absorption in subjects with cystic fibrosis, pancreatic insufficiency, and cystic fibrosis-related diabetes mellitus receiving a novel pancreatic enzyme product, ALTU-135 [abstract]. Pediatric Pulmonology 2006;41 (Suppl 29):386. [CFGD Register: GN203e]
15. Chernoff RG, Ireys HT, DeVet KA, Kim YJ. A randomized, controlled trial of a community-based support program for families of children with chronic illness: pediatric outcomes. Archives of Pediatrics and Adolescent Medicine 2002;156(6):533-9. [CFGD Register: MH13b]
16. Ireys HT, Chernoff R, DeVet KA, Kim Y. Maternal outcomes of a randomized controlled trial of a community-based support program for families of children with chronic illnesses. Archives of Pediatrics and Adolescent Medicine 2001;155(7):771-7. [CFGD Register: MH13a]
17. Driscoll KA, Johnson SB, Barker D, Quittner AL, Deeb LC, Geller DE, et al. Risk factors associated with depressive symptoms in caregivers of children with type 1 diabetes or cystic fibrosis. Journal of Pediatric Psychology 2010;35(8):814-22. [CFGD Register: CO49b; ]
18. Driscoll KA, Johnson SB, Tang Y, Yang F, Deeb LC, Silverstein JH. Does blood glucose monitoring increase prior to clinic visits in children with type 1 diabetes?. Diabetes Care 2011;34(10):2170-3. [CFGD Register: CO49c; ]
19. Driscoll KA, Killian M, Johnson SB, Silverstein JH, Deeb LC. Predictors of study completion and withdrawal in a randomized clinical trial of a pediatric diabetes adherence intervention. Contemporary Clinical Trials 2009;30(3):212-20. [CFGD Register: CO49a; ]
20. Franzese A, Spagnuolo MI, Sepe A, Valerio G, Mozzillo E, Raia V. Can glargine reduce the number of lung infections in patients with cystic fibrosis-related diabetes?. Diabetes Care 2005;28(9):2333.
21. Hardin DS, Rice J, Rice M, Rosenblatt R. Use of the insulin pump in treat cystic fibrosis related diabetes. Journal of Cystic Fibrosis 2009;8(3):174-8.
22. König P, Goldstein D, Poehlmann M, Rife D, Ge B, Hewett J. Effect of nebulized albuterol on blood glucose in patients with diabetes mellitus with and without cystic fibrosis. Pediatric Pulmonology 2005;40(2):105-8. [CFGD Register: CO23]
23. Mahroukh R, Chapman K, Stewart C, Kelly E, Hanna A, Wilson DC, et al. Changes in response to insulin and the effects of varying glucose tolerance on whole-body protein metabolism in patients with cystic fibrosis. American Journal of Clinical Nutrition 2005;81(2):421-6.
24. Marshall BC, Butler SM, Stoddard M, Moran AM, Liou TG, Morgan WJ, et al. Epidemiology of cystic fibrosis-related diabetes. Journal of Pediatrics 2005;146(5):681-7.
25. Milla CE, Billings J, Moran A. Diabetes is associated with dramatically decreased survival in female but not male subjects with cystic fibrosis. Diabetes Care 2005;28(9):2141-4.
26. Minicucci L. New diagnostic and therapeutic approaches in cystic fibrosis related diabetes (CFRD) [abstract]. Journal of Cystic Fibrosis 2008;7(Suppl 3):S6, Abstract no: R25. [CFGD Register: CO42a]
27. Minicucci L, Casciaro R, De Alessandri A, Haupt M, Caso M, Lucidi V, et al. Efficacy of slow release insulin in patients with cystic fibrosis and glucide intolerance [abstract]. Journal of Cystic Fibrosis 2009;8 (Suppl 2):S82, Abstract no: 331. [CFGD Register: CO42b]
28. Onady GM, Langdon LJ. Insulin versus oral agents in the management of Cystic Fibrosis Related Diabetes: a case based study. BMC Endocrine Disorders 2006;6:4. [PUBMED: 16790062]
29. Peraldo M, Fasulo A, Chiappini E, Milio C, Marianelli L. Evaluation of glucose tolerance and insulin secretion in cystic fibrosis patients. Hormone Research 1998;49(2):65-71.
30. Reali MF, Festini F, Neri AS, Taccetti G, Repetto T, Chiarelli F, et al. Use of continuous subcutaneous insulin infusion in cystic fibrosis patients with cystic fibrosis-related diabetes awaiting transplantation. Journal of Cystic Fibrosis 2006;5(1):67-8.
31. Sulli N, Bertasi S, Zullo S, Shashaj B. Use of continuous subcutaneous insulin infusion in patients with cystic fibrosis related diabetes: Three case reports. Journal of Cystic Fibrosis 2007;6(3):237-40.
32. Teeter JG, the Exubera ® Phase 3 Study Group, Pfizer Global Research and Development GCU. One-year pulmonary safety and efficacy of inhaled insulin as adjunctive therapy in type 2 diabetes patients poorly controlled on oral agent monotherapy [abstract]. European Respiratory Journal 2004;24(Suppl 48):P3773. [CFGD Register: CO36]
33. Ward SA, Tomezsko JL, Holsclaw DS, Paolone AM. Energy expenditure and substrate utilization in adults with cystic fibrosis and diabetes mellitus. American Journal of Clinical Nutrition 1999;69(5):913-9.
34. de Lind van Wijngaarden-van den Berg JMW, van der Meer R, Heijerman HGM. A placebo-controlled trial of insulin therapy with or without adjuvant metformin in patients with cystic fibrosis-related diabetes (CFRD) [abstract]. Journal of Cystic Fibrosis 2014;13 Suppl 2:S12, Abstract no: WS6.4. [CENTRAL: 996580; CFGD Register: CO56 ; CRS: 5500125000000680]
35. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2004;27:S15-35.
36. Adler AI, Shine B, Haworth C, Leelarathna L, Bilton D. Hyperglycemia and death in cystic fibrosis-related diabetes. Diabetes Care 2011;34(7):1577-8. [DOI: 10.2337/dc10-2289]
37. Culler FL, McKean LP, Buchanan CN, Caplan DB, Meacham LR. Glipizide treatment of patients with cystic fibrosis and impaired glucose tolerance. Journal of Pediatric Gastroenterology and Nutrition 1994;18(3):375-8.
38. Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, A Vail. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
39. Finkelstein SM, Wielinski CL, Elliott GR, Warwick WJ, Barbosa J, Wu SC, et al. Diabetes mellitus associated with cystic fibrosis. Journal of Pediatrics 1988;112(3):373-7.
40. Hardin DS, Sy JP. Effects of growth hormone treatment in children with cystic fibrosis: the National Cooperative Growth Study experience. Journal of Pediatrics 1997;131(1 Pt 2):S65-9.
41. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
42. Higgins JPT, Altman DG. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org 2011.
43. Landers A, Mathalone B, Byi KM, Hodson ME. Diabetic retinopathy in patients with cystic fibrosis related diabetes (CFRD) [abstract]. Pediatric Pulmonology 1997;24 (Suppl 14):306.
44. Lanng S, Thorsteinsson B, Nerup J, Koch C. Diabetes mellitus in cystic fibrosis: effect of insulin therapy on lung function and infections. Acta Paediatrica 1994;83(8):849-53.
45. Moran A, Diem J, Klein DF, Levitt MD, Robertson RP. Pancreatic endocrine function in cystic fibrosis. Journal of Pediatrics 1991;118(5):715-23.
46. Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Onady G, et al. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care 2010;33(12):2697-708.
47. Quittner AL, Modi AC, Wainwright C, Otto K, Kirihara J, Montgomery AB. Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 2009;135(6):1610-8.
48. Rosenecker J, Eichler I, Barmeier H, von der Hardt H. Diabetes mellitus and cystic fibrosis: comparison of clinical parameters in patients treated with insulin versus oral glucose-lowering agents. Pediatric Pulmonlogy 2001;32(5):351-5.
49. Schwarzenberg SJ, Thomas W, Olsen TW, Grover T, Walk D, Milla C, et al. Microvascular complications in cystic fibrosis-related diabetes. Diabetes Care 2007;30(5):1056-61.
50. Onady GM, Stolfi A. Insulin and oral agents for managing cystic fibrosis-related diabetes. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD004730.pub2]
51. Onady GM, Stolfi A. Insulin and oral agents for managing cystic fibrosis-related diabetes. Cochrane Database of Systematic Reviews 2013, Issue 7. [DOI: 10.1002/14651858.CD004730.pub3]